Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bioscience Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,203,104

308 payments

Through program year 2025, Bioscience Research LLC is reported as receiving $3,203,104 in research payments, across 308 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $139,123 56
2024 Research $414,714 45
2023 Research $416,411 41
2022 Research $757,550 51
2021 Research $625,795 49
2020 Research $640,895 33
2019 Research $208,616 33

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $1,465,514 79 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $746,408 21 payments
  3. ITI, Inc. $366,534 47 payments
  4. Allergan Inc. $267,671 44 payments
  5. AbbVie, Inc. $138,039 67 payments
  6. Janssen Research & Development, LLC $110,527 24 payments
  7. Supernus Pharmaceuticals, Inc. $69,084 17 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $26,099 5 payments
  9. Adlon Therapeutics L.P. $6,000 1 payment
  10. Sunovion Pharmaceuticals Inc. $5,978 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $722,943 56 payments
  2. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $319,895 2 payments
  3. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $256,064 16 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $250,264 4 payments
  5. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $222,812 3 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $197,170 22 payments
  7. 217-Mdd-303 $166,612 5 payments
  8. An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $159,708 23 payments
  9. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 $97,482 20 payments
  10. A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Rapastinel As Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder $70,736 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record